Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is employed in several hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): achieves disease control by inhibiting BCR‑ABL‑driven proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): promotes remission through targeted kinase blockade. - Gastrointestinal stromal tumor (GIST): reduces tumor size and progression by targeting c‑KIT and PDGFR signaling.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet or face. - Muscle cramps or pain. - Fatigue or weakness. - Diarrhea or abdominal discomfort. - Rash or mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia or thrombocytopenia. - Cardiac failure or reduced left‑ventricular ejection fraction. - Pulmonary arterial hypertension. - Severe allergic reactions including anaphylaxis.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood counts: regular CBC to detect neutropenia or anemia. - Assess hepatic function: periodic liver‑function tests are recommended. - Evaluate cardiac status: baseline and follow‑up echocardiograms for patients at risk. - Avoid use in patients with known hypersensitivity to Imatinib or its excipients. - Adjust dose in severe renal impairment: consider renal function before dosing. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Imatinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium: can decrease absorption. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmia. - Concomitant use with other tyrosine‑kinase inhibitors.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole). - Moderate CYP3A4 inducers (e.g., phenobarbital, phenytoin). - Warfarin: may enhance anticoagulant effect. - Proton‑pump inhibitors: possible reduction in bioavailability. - Herbal supplements such as St. John’s wort.